Daniel T Starczynowski
Overview
Explore the profile of Daniel T Starczynowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
5197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
Aggarwal R, Sidoli S, Wang J, Sahu S, Sanawar R, Gupta V, et al.
Clin Cancer Res
. 2024 Dec;
31(4):746-755.
PMID: 39704655
Purpose: Even though smoking is associated with lung cancer, the exact molecular pathways that link carcinogens with inflammation and oncogenic transformation are not well elucidated. Two major carcinogens in cigarette...
2.
Wang Y, Xiu Y, Dong Q, Zhao J, Neumbo K, Miyagi M, et al.
Blood Adv
. 2024 Dec;
9(4):844-855.
PMID: 39626355
Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein with forkhead-associated domain B (TIFAB), an inhibitor of NF-κB signaling, plays critical roles in hematopoiesis, myelodysplastic neoplasms, and leukemia. We previously demonstrated...
3.
Drucker M, Lee D, Zhang X, Kain B, Bowman M, Nicolet D, et al.
bioRxiv
. 2024 Nov;
PMID: 39605444
Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing cannot fully...
4.
Hoyt S, Finocchio C, Croll E, Tawa G, Li H, Ma L, et al.
ACS Med Chem Lett
. 2024 Nov;
15(11):1843-1851.
PMID: 39563805
We report the discovery of an imidazopyridine series of IRAK1/4/pan-FLT3 kinase inhibitors. Optimization of this series has produced compound which displays potent and selective inhibition of IRAK1, IRAK4, FLT3, and...
5.
Culver-Cochran A, Hassan A, Hueneman K, Choi K, Ma A, VanCauwenbergh B, et al.
Nat Commun
. 2024 Oct;
15(1):9189.
PMID: 39448591
Acute myeloid leukemia (AML) is a deadly hematopoietic malignancy. Although many patients achieve complete remission with standard induction therapy, a combination of cytarabine and anthracycline, ~40% of patients have induction...
6.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
7.
Stepanchick E, Wilson A, Sulentic A, Choi K, Hueneman K, Starczynowski D, et al.
Leukemia
. 2024 Jun;
38(8):1787-1798.
PMID: 38937548
Germline heterozygous mutations in DDX41 predispose individuals to hematologic malignancies in adulthood. Most of these DDX41 mutations result in a truncated protein, leading to loss of protein function. To investigate...
8.
Barreyro L, Sampson A, Hueneman K, Choi K, Christie S, Ramesh V, et al.
iScience
. 2024 May;
27(6):109809.
PMID: 38784013
Dysregulated innate immune signaling is linked to preleukemic conditions and myeloid malignancies. However, it is unknown whether sustained innate immune signaling contributes to malignant transformation. Here we show that cell-intrinsic...
9.
Matsui S, Ri C, Bolanos L, Choi K, Shibamiya A, Ishii A, et al.
Leukemia
. 2024 Apr;
38(5):1032-1045.
PMID: 38609495
TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Although altered TRAF6 expression is observed in human acute myeloid leukemia (AML),...
10.
Laranjeira A, Kong T, Snyder S, Fulbright M, Fisher D, Starczynowski D, et al.
Blood
. 2024 Mar;
143(23):2414-2424.
PMID: 38457657
Hyperactivation of the NF-κB cascade propagates oncogenic signaling and proinflammation, which together augments disease burden in myeloproliferative neoplasms (MPNs). Here, we systematically ablate NF-κB signaling effectors to identify core dependencies...